Inactivation of the tissue inhibitor of metalloproteinases-2 gene by promoter hypermethylation in lymphoid malignancies

Oliver Galm, Hiromu Suzuki, Yoshimitsu Akiyama, Manel Esteller, Malcolm V Brock, Rainhardt Osieka, Stephen B Baylin, James G. Herman

Research output: Contribution to journalArticle

Abstract

The tissue inhibitor of metalloproteinases-2 (TIMP-2) is known to antagonize matrix metalloproteinase activity and to suppress tumor growth, angiogenesis, invasion and metastasis. We analysed the methylation status of the CpG island in the TIMP-2 promoter region by methylation-specific polymerase chain reaction (MSP) in hematopoietic cell lines. TIMP-2 promoter hypermethylation in the lymphoma cell line Raji and the leukemia cell line KG1a was associated with transcriptional repression. Treatment with the demethylating agent 5-aza-2′-deoxycytidine resulted in TIMP-2 upregulation in both cell lines. TIMP-2 was expressed in the cell lines HL60, U266 and XG1, which carry an unmethylated promoter region. MSP analysis of primary patient samples revealed aberrant methylation of TIMP-2 in 33/90 (36.7%) cases of non-Hodgkin's lymphoma (NHL), but not in normal peripheral blood lymphocytes as well as in nonmalignant bone marrow and lymph nodes. The frequency of TIMP-2 methylation was slightly higher in aggressive NHL subtypes compared to those with an indolent subtype (38.6 versus 33.3%). In contrast, TIMP-2 was not hypermethylated in any of the 40 cases of acute myelogenous leukemia examined. We conclude that promoter hypermethylation of TIMP-2 is a novel epigenetic event in the pathogenesis of lymphoid malignancies and may contribute to a more aggressive NHL phenotype.

Original languageEnglish (US)
Pages (from-to)4799-4805
Number of pages7
JournalOncogene
Volume24
Issue number30
DOIs
StatePublished - Jul 14 2005

Fingerprint

Tissue Inhibitor of Metalloproteinase-2
Genes
Neoplasms
Methylation
Cell Line
Non-Hodgkin's Lymphoma
decitabine
Genetic Promoter Regions
Choristoma
CpG Islands
Matrix Metalloproteinases
Acute Myeloid Leukemia
Epigenomics
Lymphoma
Leukemia
Up-Regulation
Lymph Nodes
Bone Marrow
Lymphocytes
Neoplasm Metastasis

Keywords

  • Angiogenesis
  • Matrix metalloproteinases
  • Non-Hodgkin's lymphoma
  • Promoter hypermethylation

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Inactivation of the tissue inhibitor of metalloproteinases-2 gene by promoter hypermethylation in lymphoid malignancies. / Galm, Oliver; Suzuki, Hiromu; Akiyama, Yoshimitsu; Esteller, Manel; Brock, Malcolm V; Osieka, Rainhardt; Baylin, Stephen B; Herman, James G.

In: Oncogene, Vol. 24, No. 30, 14.07.2005, p. 4799-4805.

Research output: Contribution to journalArticle

Galm, Oliver ; Suzuki, Hiromu ; Akiyama, Yoshimitsu ; Esteller, Manel ; Brock, Malcolm V ; Osieka, Rainhardt ; Baylin, Stephen B ; Herman, James G. / Inactivation of the tissue inhibitor of metalloproteinases-2 gene by promoter hypermethylation in lymphoid malignancies. In: Oncogene. 2005 ; Vol. 24, No. 30. pp. 4799-4805.
@article{ecd77816615b4be8ba5cfb12e8f9924b,
title = "Inactivation of the tissue inhibitor of metalloproteinases-2 gene by promoter hypermethylation in lymphoid malignancies",
abstract = "The tissue inhibitor of metalloproteinases-2 (TIMP-2) is known to antagonize matrix metalloproteinase activity and to suppress tumor growth, angiogenesis, invasion and metastasis. We analysed the methylation status of the CpG island in the TIMP-2 promoter region by methylation-specific polymerase chain reaction (MSP) in hematopoietic cell lines. TIMP-2 promoter hypermethylation in the lymphoma cell line Raji and the leukemia cell line KG1a was associated with transcriptional repression. Treatment with the demethylating agent 5-aza-2′-deoxycytidine resulted in TIMP-2 upregulation in both cell lines. TIMP-2 was expressed in the cell lines HL60, U266 and XG1, which carry an unmethylated promoter region. MSP analysis of primary patient samples revealed aberrant methylation of TIMP-2 in 33/90 (36.7{\%}) cases of non-Hodgkin's lymphoma (NHL), but not in normal peripheral blood lymphocytes as well as in nonmalignant bone marrow and lymph nodes. The frequency of TIMP-2 methylation was slightly higher in aggressive NHL subtypes compared to those with an indolent subtype (38.6 versus 33.3{\%}). In contrast, TIMP-2 was not hypermethylated in any of the 40 cases of acute myelogenous leukemia examined. We conclude that promoter hypermethylation of TIMP-2 is a novel epigenetic event in the pathogenesis of lymphoid malignancies and may contribute to a more aggressive NHL phenotype.",
keywords = "Angiogenesis, Matrix metalloproteinases, Non-Hodgkin's lymphoma, Promoter hypermethylation",
author = "Oliver Galm and Hiromu Suzuki and Yoshimitsu Akiyama and Manel Esteller and Brock, {Malcolm V} and Rainhardt Osieka and Baylin, {Stephen B} and Herman, {James G.}",
year = "2005",
month = "7",
day = "14",
doi = "10.1038/sj.onc.1208599",
language = "English (US)",
volume = "24",
pages = "4799--4805",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "30",

}

TY - JOUR

T1 - Inactivation of the tissue inhibitor of metalloproteinases-2 gene by promoter hypermethylation in lymphoid malignancies

AU - Galm, Oliver

AU - Suzuki, Hiromu

AU - Akiyama, Yoshimitsu

AU - Esteller, Manel

AU - Brock, Malcolm V

AU - Osieka, Rainhardt

AU - Baylin, Stephen B

AU - Herman, James G.

PY - 2005/7/14

Y1 - 2005/7/14

N2 - The tissue inhibitor of metalloproteinases-2 (TIMP-2) is known to antagonize matrix metalloproteinase activity and to suppress tumor growth, angiogenesis, invasion and metastasis. We analysed the methylation status of the CpG island in the TIMP-2 promoter region by methylation-specific polymerase chain reaction (MSP) in hematopoietic cell lines. TIMP-2 promoter hypermethylation in the lymphoma cell line Raji and the leukemia cell line KG1a was associated with transcriptional repression. Treatment with the demethylating agent 5-aza-2′-deoxycytidine resulted in TIMP-2 upregulation in both cell lines. TIMP-2 was expressed in the cell lines HL60, U266 and XG1, which carry an unmethylated promoter region. MSP analysis of primary patient samples revealed aberrant methylation of TIMP-2 in 33/90 (36.7%) cases of non-Hodgkin's lymphoma (NHL), but not in normal peripheral blood lymphocytes as well as in nonmalignant bone marrow and lymph nodes. The frequency of TIMP-2 methylation was slightly higher in aggressive NHL subtypes compared to those with an indolent subtype (38.6 versus 33.3%). In contrast, TIMP-2 was not hypermethylated in any of the 40 cases of acute myelogenous leukemia examined. We conclude that promoter hypermethylation of TIMP-2 is a novel epigenetic event in the pathogenesis of lymphoid malignancies and may contribute to a more aggressive NHL phenotype.

AB - The tissue inhibitor of metalloproteinases-2 (TIMP-2) is known to antagonize matrix metalloproteinase activity and to suppress tumor growth, angiogenesis, invasion and metastasis. We analysed the methylation status of the CpG island in the TIMP-2 promoter region by methylation-specific polymerase chain reaction (MSP) in hematopoietic cell lines. TIMP-2 promoter hypermethylation in the lymphoma cell line Raji and the leukemia cell line KG1a was associated with transcriptional repression. Treatment with the demethylating agent 5-aza-2′-deoxycytidine resulted in TIMP-2 upregulation in both cell lines. TIMP-2 was expressed in the cell lines HL60, U266 and XG1, which carry an unmethylated promoter region. MSP analysis of primary patient samples revealed aberrant methylation of TIMP-2 in 33/90 (36.7%) cases of non-Hodgkin's lymphoma (NHL), but not in normal peripheral blood lymphocytes as well as in nonmalignant bone marrow and lymph nodes. The frequency of TIMP-2 methylation was slightly higher in aggressive NHL subtypes compared to those with an indolent subtype (38.6 versus 33.3%). In contrast, TIMP-2 was not hypermethylated in any of the 40 cases of acute myelogenous leukemia examined. We conclude that promoter hypermethylation of TIMP-2 is a novel epigenetic event in the pathogenesis of lymphoid malignancies and may contribute to a more aggressive NHL phenotype.

KW - Angiogenesis

KW - Matrix metalloproteinases

KW - Non-Hodgkin's lymphoma

KW - Promoter hypermethylation

UR - http://www.scopus.com/inward/record.url?scp=23044495284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044495284&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1208599

DO - 10.1038/sj.onc.1208599

M3 - Article

C2 - 15870703

AN - SCOPUS:23044495284

VL - 24

SP - 4799

EP - 4805

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 30

ER -